David W. Moskowitz MD
firstname.lastname@example.orgWGNU 920 AM
St. Louis Urban Forum
Tel. 314-454-0400 / 877-537-1329
Call-in numbers: 314-448-4325/1-877-920-9468
February 8, 2010—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced that tomorrow will be its second radio show on WGNU 920 AM. The show, called “To Your Health,” will be emceed by GenoMed’s CEO and Chief Medical Officer, David Moskowitz MD. Everybody is encouraged to call in to join the conversation.
Dr. Moskowitz said, “It’s not enough to discover how to prevent 90% of dialysis, as I did 15 years ago. People also need to hear about it. Since the public health apparatus of the US as well as other countries has so far been completely silent on this matter, it’s up to us to get the word out ourselves.”
Dr. Moskowitz continued, “My paper showing how to prevent at least 90% of kidney failure was published in September, 2002. Although kidney failure claims the lives of 300 Americans every day, it affects African-Americans 5 times more, and Hispanics 3 times more, than whites. Medicare currently spends $40 billion a year on this disease, but for the past 7 years has shown no interest in eliminating it and cutting its budget by 10%.”
Dr. Moskowitz ended by saying, “Congress says it has no idea why healthcare costs keep going up. All they have to do is look at this example to understand why our healthcare system is bankrupting us individually, as well as nationally.”
About GenoMed (www.genomed.com)
GenoMed was founded in 2001 by Dr. David Moskowitz, a kidney specialist. The company recently began a “Dialysis-Free in 5” campaign: it will gladly work with any community in the world that wants to eliminate 90% of dialysis within 5 years. GenoMed hopes to make St. Louis dialysis-free by 2015.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) finances and treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.